Noa Krawczyk
Noa Krawczyk, PhD
NYU Langone Health, Division of Epidemiology, Center for Opioid Epidemiology and Policy, Department of Population Health - Assistant Professor
PhD, Mental Health, Johns Hopkins Bloomberg School of Public Health
BA, Biology, Hunter College at the City University of New York – Macaulay Honors College
Research Interests
Substance use, Opioids, Overdose, Health services, Mental health, Criminal justice, Treatment
Noa Krawczyk is an Assistant Professor in the Department of Population Health at NYU School of Medicine and a member of the Center for Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with health organizations, public health and government agencies and advancing science that can help inform evidence-based policies and practices that reduce harm and promote long term recovery.
Principal Investigator, Beyond Treatment Initiation: Enhancing Opioid Use Disorder Care Transitions Across Health System Touchpoints. Active
Principal Investigator, Trends in Psychosis Related to Hospitalizations Among Youth Following Cannabis Legalization in Colorado. Completed


Kline D, Bunting AM, Hepler SA, Rivera-Aguirre A, Krawczyk N, Cerda M (2023).
State-level history of overdose deaths involving stimulants in the United States, 1999-2020
American Journal of Public Health, 113 (9), 991-999. doi: 10.2105/AJPH.2023.307337. PMCID: PMC10413741.

Conway A, Krawczyk N, McGaffey F, Doyle S, Baaklini V, Marshall AD, Treloar C, Davis CS, Colledge-Frisby S, Grebely J, Cerda M (2023).
Typology of laws restricting access to methadone treatment in the United States: A latent class analysis
International Journal of Drug Policy, 119, 104141. doi: 10.1016/j.drugpo.2023.104141.

Allen B, Basaraba C, Corbeil T, Rivera BD, Levin FR, Martinez DM, Schultebraucks K, Henry BF, Pincus HA, Arout C, Krawczyk N (2023).
Racial differences in COVID-19 severity associated with history of substance use disorders and overdose: Findings from multi-site electronic health records in New York City
Preventive Medicine, 172, 107533. doi: 10.1016/j.ypmed.2023.107533. PMCID: PMC10155467.

Krawczyk N, Rivera BD, King C, Dooling BCE (2023).
Pandemic telehealth flexibilities for buprenorphine treatment: A synthesis of evidence and policy implications for expanding opioid use disorder care in the U.S.
Health Affairs Scholar, 1 (1), qxad013. doi: 10.1093/haschl/qxad013.

Bastos FI, Krawcyzk N (2023).
Reports of rising use of fentanyl in contemporary Brazil is of concern, but a US-like crisis may still be averted
Lancet Regional Health - Americas, 23, 100507. doi: 10.1016/j.lana.2023.100507.


Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D (2019).
Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap
Journal of Substance Abuse Treatment, 103, 1-8. doi: 10.1016/j.jsat.2019.05.002. PMCID: PMC6612429.

Krawczyk N, Picher CE, Feder KA, Saloner B (2017).
Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine
Health Affairs, 36 (12), 2046-2053. doi: 10.1377/hlthaff.2017.0890. PMCID: PMC6035729.

Dr. Krawczyk's MyBibliography Profile
Selected Press